A call to reform the taxonomy of human disease

Nature Reviews Drug Discovery

Volumn 10, Issue 9, 2011, Pages 641-642

  Kola, Ismail ^a   Bell, John ^b  

^a UCB Nv   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; B RAF KINASE; B RAF KINASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESEARCH; ELECTRONIC MEDICAL RECORD; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL RESEARCH; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TAXONOMY;

CLASSIFICATION; CLINICAL TRIALS AS TOPIC; DISEASE; DRUG INDUSTRY; GENOMICS; MOLECULAR BIOLOGY; RESEARCH DESIGN;

EID: 80052245860     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3534     Document Type: Note

References (4)

1. Kola, I. and Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
2. Arrowsmith, J. Phase II failures: 2008-2010. Nature Rev. Drug Discov.10, 328-329 (2011).
3. Billings, L. K. & Florez, J. C. The genetics of type 2 diabetes: what have we learned from GWAS? Ann. NY Acad. Sci. 1212, 59-77 (2010).
4. Hyman, S. E. Can neuroscience be integrated into the DSM-V? Nature Rev. Neurosci. 8, 725-732 (2007). (Pubitemid 47283150)